TrialThe Journal of infectious diseases2024

A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.

Shon Remich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.